Finance

Beta
Lists
PACB:NASDAQ
Pacific Biosciences of California Inc
၁.၅၈ US$
+၆.၀၄%
(+၀.၀၉၀) 1D
၁.၅၆ US$
-၁.၂၇% (-၀.၀၂၀)
After hours
Closed: ဇွန် ၁, GMT-၄ ၁၆:၀၀:၀၀  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PACB...
Open
၁.၄၅ US$
High
၁.၆၂ US$
Low
၁.၄၄ US$
Mkt. cap
၄၉.၀၈ ကုဋေ
Avg. vol.
၆.၄၆ သန်း
Volume
၈.၂၀ သန်း
52-wk high
၂.၇၃ US$
52-wk low
၀.၉၆ US$
EPS
-၀.၄၃ US$
Beta
၂.၄၀
Shares outstanding
၃၁.၀၆ ကုဋေ
No. of employees
၄၈၅
Open
၁.၄၅ US$
High
၁.၆၂ US$
Low
၁.၄၄ US$
Mkt. cap
၄၉.၀၈ ကုဋေ
Avg. vol.
၆.၄၆ သန်း
Volume
၈.၂၀ သန်း
52-wk high
၂.၇၃ US$
52-wk low
၀.၉၆ US$
EPS
-၀.၄၃ US$
Beta
၂.၄၀
Shares outstanding
၃၁.၀၆ ကုဋေ
No. of employees
၄၈၅
News stories
From sources across the web
Zacks Investment Research
Zacks Investment Research
·
ပြီးခဲ့သည့် ၇ နာရီ
PacBio Expands HiFi Sequencing Reach With New SPRQ-Nx Technology
Profile
Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing, based on the properties of zero-mode waveguides and sequencing by binding chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension. Wikipedia
About Pacific Biosciences of California Inc
CEOChristian Henry
Employees၄၈၅
Founded၂၀၀၄
HeadquartersMenlo Park, ကယ်လီဖိုးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitepacb.com
Last report
၂၀၂၆ မေ ၇
Fiscal period
Q1 2026
EPS / Est. (USD)
-၀.၁၂ US$ / -၀.၁၃ US$
+၈.၇၀%beat
Revenue / Est. (USD)
၃.၇၂ ကုဋေ / ၄.၀၀ ကုဋေ
-၇.၀၀%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
၂၀၂၅ ဇွန်
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
Revenue
၃.၉၈ ကုဋေ
၃.၈၄ ကုဋေ
၄.၄၆ ကုဋေ
၃.၇၂ ကုဋေ
Cost of goods sold
၂.၄၉ ကုဋေ
၂.၂၃ ကုဋေ
၄.၀၃ ကုဋေ
၂.၃၇ ကုဋေ
Cost of revenue
၂.၄၉ ကုဋေ
၂.၂၃ ကုဋေ
၄.၀၃ ကုဋေ
၂.၃၇ ကုဋေ
Research and development expenses
၂.၂၅ ကုဋေ
၂.၂၈ ကုဋေ
၂.၃၅ ကုဋေ
၁.၉၆ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၃.၆၂ ကုဋေ
၃.၁၁ ကုဋေ
၃.၅၈ ကုဋေ
၃.၁၂ ကုဋေ
Operating expense
၅.၉၇ ကုဋေ
၅.၅၀ ကုဋေ
၆.၄၄ ကုဋေ
၅.၁၈ ကုဋေ
Total operating expenses
၈.၄၆ ကုဋေ
၇.၇၂ ကုဋေ
၁၀.၄၇ ကုဋေ
၇.၅၄ ကုဋေ
Operating income
-၄.၄၈ ကုဋေ
-၃.၈၈ ကုဋေ
-၆.၀၁ ကုဋေ
-၃.၈၃ ကုဋေ
Other non operating income
၄.၆၇ သန်း
၂.၉၂ သန်း
၆.၄၈ သန်း
၁.၇၁ သန်း
EBT including unusual items
-၄.၁၉ ကုဋေ
-၃.၇၆ ကုဋေ
-၄.၀၂ ကုဋေ
-၈.၀၉ သန်း
EBT excluding unusual items
-၄.၁၉ ကုဋေ
-၃.၇၆ ကုဋေ
-၅.၅၃ ကုဋေ
-၃.၈၃ ကုဋေ
Income tax expense
၃.၅၀ သောင်း
၃.၈၃ သိန်း
၂.၀၂ သိန်း
၁.၈၄ သိန်း
Effective tax rate
-၀.၀၈%
-၁.၀၂%
-၀.၅၀%
-၂.၂၇%
Other operating expenses
-
-
၄.၁၈ သန်း
-
Net income
-၄.၁၉ ကုဋေ
-၃.၈၀ ကုဋေ
-၄.၀၄ ကုဋေ
-၈.၂၈ သန်း
Net profit margin
-၁၀၅.၄၄%
-၉၈.၈၅%
-၉၀.၄၃%
-၂၂.၂၆%
Earnings per share
-၀.၁၃
-၀.၁၂
-၀.၁၂
-၀.၁၂
Interest and investment income
-
-
-
-
Interest expense
-၁.၇၄ သန်း
-၁.၇၄ သန်း
-၁.၇၄ သန်း
-၁.၇၄ သန်း
Net interest expenses
-၁.၇၄ သန်း
-၁.၇၄ သန်း
-၁.၇၄ သန်း
-၁.၇၄ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၄.၁၂ ကုဋေ
-၃.၅၃ ကုဋေ
-၅.၆၃ ကုဋေ
-၃.၅၀ ကုဋေ
Gain or loss from assets sale
-
-
-
-၄.၈၁ ကုဋေ
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more